Answers are grounded in this paper and cite their sources.
Disease-modifying anti-rheumatic drugs (DMARDs) are typically used for the therapy of rheumatoid arthritis (RA), but most have some nephrotoxicity. In several clinical studies, etanercept had fewer adverse effects on renal function than other DMARDs. We report the case of a 64-year-old woman with RA and renal insufficiency on hemodialysis treated using etanercept therapy. This case suggests that etanercept therapy might be effective in the short term for such patients.
No takes yet. Share an insight, caveat, or question.
Sugioka et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: